News und Analysen
Enpro Q2 Earnings Call Highlights
Key Points
- Interested in Enpro Inc.? Here are five stocks we like better.
- Strong second-quarter performance: Sales rose 17.6% year over year to $338.8 million, while adjusted EBITDA increased
Pharma-Woche der Wahrheit: BioNTech enttäuscht, Novartis punktet bei Pluvicto
Ein Milliardenverlust bei BioNTech, eine erweiterte Zulassung für Novartis‘ Krebstherapie Pluvicto und gleich zwei…
Der Beitrag Pharma-Woche der Wahrheit: BioNTech enttäuscht, Novartis punktet bei
Merck & Co., Inc. Q2 Earnings Call Highlights
Key Points
- Interested in Merck & Co., Inc.? Here are five stocks we like better.
- Q2 revenue rose 5% to $16.6 billion, driven by oncology, animal health and newer launches. Merck reported a
Pediatrix Medical Group Q2 Earnings Call Highlights
Key Points
- Interested in Pediatrix Medical Group, Inc.? Here are five stocks we like better.
- Pediatrix reported Q2 adjusted EBITDA of $76 million and reaffirmed its full-year outlook of $280
Fresenius Aktie: Kabi treibt Gewinnsprung
Ein Quartal, das die eigenen Erwartungen übertrifft — und der Vorstand reagiert prompt mit…
Der Beitrag Fresenius Aktie: Kabi treibt Gewinnsprung erschien zuerst auf kapitalmarktexperten.de.
Quelle
Eastman Kodak Q2 Earnings Call Highlights
Key Points
- Interested in Eastman Kodak Company? Here are five stocks we like better.
- Kodak reported broad year-over-year improvement in Q2 2026: Revenue rose 18% to $311 million, gross profit
Jacobs Solutions Q3 Earnings Call Highlights
Key Points
- Interested in Jacobs Solutions Inc.? Here are five stocks we like better.
- Jacobs raised its fiscal 2026 outlook for the third consecutive quarter, targeting 9.5%–10% adjusted net
DaVita Q2 Earnings Call Highlights
Key Points
- Interested in DaVita Inc.? Here are five stocks we like better.
- DaVita reaffirmed its 2026 outlook after reporting second-quarter adjusted operating income of $579 million, adjusted
Basilea erhält zusätzliche USD 5.4 Mio. von BARDA zur Entwicklung des neuartigen Antibiotikums Ceftibuten-Ledaborbactam
Ad hoc-Mitteilung gemäss Art. 53 KR
Allschwil, 05. August 2026
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel
EQS-News: Formycon lädt zur Telefonkonferenz zu den Ergebnissen des ersten Halbjahres 2026 ein und gibt Teilnahme an internationalen Investorenkonferenzen bekannt
EQS-News: Formycon lädt zur Telefonkonferenz zu den Ergebnissen des ersten Halbjahres 2026 ein und gibt Teilnahme an internationalen Investorenkonferenzen bekannt
Viasat Q1 Earnings Call Highlights
Key Points
- Interested in Viasat Inc.? Here are five stocks we like better.
- Viasat maintained its fiscal 2027 outlook despite first-quarter revenue falling 1% to $1.2 billion and adjusted
Travere Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Travere Therapeutics, Inc.? Here are five stocks we like better.
- Record FILSPARI performance: Travere reported $169.6 million in total second-quarter revenue
Syndax Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Syndax Pharmaceuticals, Inc.? Here are five stocks we like better.
- Syndax’s Q2 revenue rose 92% year over year to $72.8 million, driven by Revuforj revenue of $54.7
Rigel Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Rigel Pharmaceuticals, Inc.? Here are five stocks we like better.
- Strong Q2 performance: Rigel reported $78.7 million in revenue and $17.3 million in net income, with
Ultragenyx Pharmaceutical Q2 Earnings Call Highlights
Key Points
- Interested in Ultragenyx Pharmaceutical Inc.? Here are five stocks we like better.
- Ultragenyx reported record Q2 revenue of $214 million, led by Crysvita’s $156 million contribution
PROCEPT BioRobotics Q2 Earnings Call Highlights
Key Points
- Interested in PROCEPT BioRobotics Corporation? Here are five stocks we like better.
- Second-quarter revenue rose 19% year over year to $94.5 million, but weaker utilization at legacy
Match Group Q2 Earnings Call Highlights
Key Points
- Interested in Match Group Inc.? Here are five stocks we like better.
- Match Group reported mixed Q2 results: Revenue fell 1% year over year to $853 million, while adjusted EBITDA
LeMaitre Vascular Q2 Earnings Call Highlights
Key Points
- Interested in LeMaitre Vascular, Inc.? Here are five stocks we like better.
- Strong quarterly performance: LeMaitre Vascular delivered 10% organic revenue growth, record operating
Gilead Sciences Q2 Earnings Call Highlights
Key Points
- Interested in Gilead Sciences, Inc.? Here are five stocks we like better.
- Base business sales rose 10% year over year to $7.6 billion, led by HIV, oncology and liver treatments
Cumberland Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Cumberland Pharmaceuticals Inc.? Here are five stocks we like better.
- Cumberland completed the sale of its branded U.S. commercial portfolio to Apotex for $100 million
Arrowhead Pharmaceuticals Q3 Earnings Call Highlights
Key Points
- Interested in Arrowhead Pharmaceuticals, Inc.? Here are five stocks we like better.
- Plozasiran delivered positive Phase III results in severe hypertriglyceridemia, reducing
Amgen Q2 Earnings Call Highlights
Key Points
- Interested in Amgen Inc.? Here are five stocks we like better.
- Amgen reported strong second-quarter results, with revenue exceeding $10 billion, up 10% year over year, and raised its
ACADIA Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in ACADIA Pharmaceuticals Inc.? Here are five stocks we like better.
- Second-quarter revenue rose 17% year over year to $308 million, driven by DAYBUE sales of $125 million
BellRing Brands Q3 Earnings Call Highlights
Key Points
- Interested in BellRing Brands Inc.? Here are five stocks we like better.
- Third-quarter sales rose 4%, led by better-than-expected performance from Premier Protein and a 27% increase
Armada Hoffler Properties Q2 Earnings Call Highlights
Key Points
- Interested in Armada Hoffler Properties, Inc.? Here are five stocks we like better.
- Armada Hoffler raised its 2026 FFO guidance to $0.53–$0.57 per diluted share after reporting